GB Sciences, Inc. (GBLX)
OTCMKTS: GBLX · Delayed Price · USD
0.0068
+0.0003 (4.89%)
Apr 19, 2024, 1:47 PM EDT - Market open
Company Description
GB Sciences, Inc., a phytomedical research and biopharmaceutical drug development company, engages in the research and development of plant-based medicines.
The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market.
Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs.
The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016.
GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.
GB Sciences, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | John Claybron Poss |
Contact Details
Address: 6450 Cameron Street #110a Las Vegas, Nevada 89118 United States | |
| Phone | (844) 843-2569 |
| Website | gbsciences.com |
Stock Details
| Ticker Symbol | GBLX |
| Exchange | OTCMKTS |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001165320 |
| CUSIP Number | 361544109 |
| ISIN Number | US3615441090 |
| Employer ID | 59-3733133 |
| SIC Code | 1311 |
Key Executives
| Name | Position |
|---|---|
| John Claybron Poss | Chief Executive Officer, Interim Chief Financial Officer and Chairman |
| Dr. Andrea Small-Howard M.B.A., MBA, Ph.D. | Chairman of Scientific Advisory Board, Chief Science Officer, President and Director |
| Gary R. Henrie Esq. | Securities Counsel and Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 12, 2024 | 10-Q | Quarterly Report |
| Nov 20, 2023 | 10-Q | Quarterly Report |
| Nov 14, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Oct 10, 2023 | 424B3 | Prospectus |
| Sep 8, 2023 | 8-K | Current Report |
| Aug 14, 2023 | 10-Q | Quarterly Report |
| Aug 2, 2023 | D | Notice of Exempt Offering of Securities |
| Jul 14, 2023 | 10-K | Annual Report |
| Jun 30, 2023 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Apr 14, 2023 | 8-K | Current Report |